Explore the Companies, Modalities and Breakthroughs Shaping the Future of RNA Therapeutics
Attendees learned from the companies moving into the clinic, explored emerging modalities beyond splice modulation, and discovered how the field tackled its biggest challenges: selectivity, functional modulation, and target validation.
The RNA-targeted small molecule field is reaching a critical inflection point.
Underscored by clinical advances including ReviR Therapeutics’ first participant dosed in a Phase 1 study of RTX-117 and Remix Therapeutics’ reporting positive Phase 1/2 data for REM-422, clinical programs are advancing, pharma interest is growing, and new approaches are expanding what is possible beyond traditional splice modulation.
Over 80 RNA-targeted drug discovery leaders came together to:
- Access new data from companies advancing RNA-targeted therapies toward the clinic
- Explore emerging modalities including RNA degraders, covalent binders, and epitranscriptomic approaches
- Tackle key challenges in target selection, functional modulation, and selectivity
- Benchmark strategies with leading biotech, pharma, and academic experts
- Connect with the companies shaping the future of RNA-targeted therapeutic
The 9th RNA-Targeted Drug Discovery & Development Summit brought together leaders from PTC Therapeutics, Remix Therapeutics, ReviR Therapeutics, AstraZeneca, Sanofi, Atomic AI, Syrna Therapeutics, Ribonaut Therapeutics, and more to share insights, forge partnerships, and accelerate the future of RNA-targeted drug discovery.
Meet The Companies Defining The Future Of The Field
Explore the 2026 Event Guide
- Connect with 80+ RNA-targeted small molecule leaders from biotech, pharma, and academia
- Hear 18+ case studies spanning discovery, design, validation, and translation
- Participate in 3 interactive workshops tackling the field's biggest challenges
- Discover new insights across splice modulation, direct RNA targeting, degraders, and covalent binders
- Learn how leading teams are approaching screening, selectivity, and target validation
- Join the only conference dedicated exclusively to RNA-targeted small molecules
The Questions Driving RNA-Targeted Drug Discovery Forward
Why haven't we seen more clinical success stories?
How do we move beyond RNA binding to achieve functional modulation?
Which targets are genuinely therapeutically relevant?
How can we improve selectivity and reduce off-target effects?
What novel chemistries will unlock currently inaccessible RNA targets?
How close are we to broader pharma adoption?
Join the community working to answer these questions.
2026 Partner
Explore Related Events
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.